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Title: Shedding light on the HTA consultancy market for pharmaceuticals: Insights from Poland 
 
Abstract 
Research on health technology assessment (HTA) from a policy perspective typically examines public HTA 
bodies, with little attention devoted to how manufacturers develop their evidence submissions. Taking Poland as 
a crucial case, we explored the market of HTA consultancy firms which assist drug manufacturers in developing 
these submissions, called HTA reports. We reviewed 318 HTA reports from 2012-2015, data from the Polish 
National Company Registry, the content of HTA consulting firms’ websites, and appraisal reports developed by 
the Polish HTA body. We identified HTA consultancy firms which developed 96-98% HTA reports. We found 
that the transparency of information about the authors of HTA reports provided by the HTA body had improved 
between 2012 and 2015. Six companies with market shares from 10 to 30% dominated the market. The market 
size was 5-6 million EUR annually. HTA consultancies had a broad service portfolio related to preparation of HTA 
reports. Over 90% of HTA reports did not meet the official minimum quality requirements, and only half of the 
resubmissions took into account remarks made by the HTA body. Our study provides insights into the structure, 
evolution and role of the for-profit HTA consultancy market as a crucial part of the public HTA system. This raises 
important policy points about transparency and regulation at the intersection of public and private sectors in HTA.  
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1. Introduction 
Policy studies of health technology assessment (HTA) have examined in detail public HTA bodies that evaluate 
evidence submissions supporting technologies applying for reimbursement [1-5]. However, little attention has 
been given to how manufacturers prepare these submissions. Recent research suggests that this often involves 
assistance provided by private sector consultancy firms specialising in data collection, evidence synthesis and 
report preparation [6-8]. Limited knowledge about the operation and characteristics of these firms is a major gap 
in research, given their role in the development of evidence underpinning subsequent HTA recommendations, 
often with major budgetary and public health implications. This paper contributes to addressing this gap by 
focusing on HTA consultancies in Poland, a country with a well-established HTA system. 
Consulting in HTA is part of a broader phenomenon of drug companies outsourcing services to specialist 
consultancies. A key example of this is subcontracting the conduct of clinical trials to Clinical Research 
Organizations (CROs) [9], typically explained by the increase in the magnitude of clinical research and the drive 
towards a more efficient and flexible organization of research and development [10,11]. Similar reasons, namely 
limited “head-count” within pharmaceutical companies, coupled with the rise in regulatory requirements necessary 
for obtaining public funding, are likely to drive outsourcing to HTA consultancies.  
HTA consultancy firms are private companies that generate or synthesize evidence and input for funding decisions. 
They employ experts in health economics, medicine, statistics and pharmacology, who can be described as “HTA 
professionals”. Like other experts involved in regulatory science [12], they have their professional conventions, 
experience and a shared body of knowledge and methods, developed in national and international networks, such 
as the International Society for Pharmacoeconomics and Outcomes Research and its local chapters, and specialized 
training programs, including MSc programs in health economics [13-15]. Given their highly specialized, 
knowledge based, service oriented and data driven approach, a strong HTA consulting market may function as an 
incubator of expertise, particularly important given the many recommendations to build capacity in order to 
strengthen HTA systems [17]. On the other hand, especially in countries with low public sector resources, the 
revolving door between consultancies and public HTA bodies has led to conflicts of interest, and often dramatic 
loss of expertise in the public sector [6,18-20].  
To contribute towards assessing the risks and benefits associated with HTA consultancy markets, we provide a 
first exploratory overview of the HTA consultancy market in Poland. We focus on the following objectives. First, 
to identify HTA consulting firms that collectively make up the HTA consultancy market in Poland. Second, to 
describe the HTA market structure and estimate its size. Third, to examine the evolution of the HTA consultancy 
market and the key activities of its players. Finally, to analyse the quality of HTA reports given to HTA consultancy 
firms by the Polish Agency for Health Technology Assessment (AHTAPol).  
We select Poland as a crucial case because, first, HTA consultancy firms have developed in parallel to the 
institutionalization of public HTA in Poland. Notably, the first commercial HTA consultancy firms were 
established around 2002 in Kraków by former employees of the first public organization working on HTA [21]. 
Since then, experts representing those firms have contributed to the development of the official HTA guidelines 
issued by the AHTAPol [22-24]. Second, since its establishment in 2005 [25], the AHTAPol has consistently 
pursued an HTA model similar to the Single Technology Appraisal (STA) process developed by the Scottish 
Medicine Consortium and adopted by the English National Institute for Health and Care Excellence in 2005 
[26,27]. Within the STA process, the core pharmacoeconomic evidence is generated by manufacturers. These 
evidence submissions, which we simply call “HTA reports”, are then evaluated by internal or external experts, 
whose appraisal (called “verification analysis” in Poland) forms the basis of subsequent discussions held by the 
members of an appraisal committee. Consistent reliance on this model of HTA in Poland has created conditions 
for the emergence of consultancy firms assisting manufacturers in preparing country-specific HTA reports based 
on the AHTAPol’s guidelines. Third, as HTA and the reimbursement processes are interconnected and some staff 
in HTA consultancy firms have worked for public institutions involved in drug reimbursement, HTA consultancies 
are uniquely positioned to advise manufacturers on the broader regulatory environment [19,20], which has evolved 
significantly since the early 2000s [28,29]. Fourth, as Poland is an important European pharmaceutical market 
there are a steady number of drugs applying for HTA appraisals annually ranging from approximately 80 to 100 
[28,29]. This, too, is a good proxy for a strong demand for services provided by HTA consultancy firms. Finally, 
unlike in some other countries, the analysis of the HTA consultancy market in Poland has been enabled by the 
public availability of documents generated at various stages of the HTA process [30-34]. 
 
2. Materials and methods 
We adopted a mixed methods study design, summarized in Table 1.  
The extent to which we were able to identify HTA consultancy firms was affected by the transparency of 
information regarding the authors of the HTA reports, as provided by the AHTAPol. To identify the HTA 
consultancy firms we extracted data from HTA reports submitted by drug manufacturers and published on the 
AHTAPol website [35]. We considered HTA reports submitted to the AHTAPol between 2012 and 2015. We 
selected 2012 as the start date because in this year the AHTAPol started publishing HTA reports under the 
provisions of the Reimbursement Act in 2011. The AHTAPol has a duty, introduced by the Reimbursement Act, 
to make HTA reports and corresponding verification analysis publicly available online [36]. We end our analysis 
in 2015, as this was the last year for which a full set of HTA reports and verification analyses was available at the 
time of data collection. From January to March 2018, we downloaded and reviewed all analyses available as part 
of each HTA report, namely decision problem analysis, clinical assessment, economic analysis, budget impact 
analysis, and rationalization analysis (these are proposals for addressing additional expenditure resulting from the 
reimbursement of the health technology; they outline where savings could be achieved in the pharmaceutical 
spending to ensure sufficient resources for the new drug). Given frequent redactions in the available analyses (e.g. 
author names or organizational details removed), we had to rely, where necessary, on logos, document design or 
website links to identify authors of analyses. Appendix I/A describes the complete process of identifying HTA 
consultancy firms. 
To analyze the HTA market structure we calculated the market share of each identified company based on the 
HTA reports. We calculated the number of HTA reports prepared by HTA consultancy firms on a yearly basis. As 
one type of analysis in the HTA reports, decision problem analysis, was sometimes a subsection of the clinical 
assessment analysis or, at other times, a standalone document, we excluded decision problem analyses from the 
analysis. 
We estimated the size of the Polish HTA market using the number of HTA reports prepared by each HTA 
consultancy firm and their annual net revenues from sales obtained from the Polish National Company Registry 
[37]. As the data included in the Registry was limited and insufficiently detailed, our calculations are based on 
certain assumptions, which are detailed in Appendix I/B, including our approach to market size estimation. 
To describe evolution and the key activities of HTA consultancy firms we analyzed data downloaded in June and 
July 2018 from the websites of HTA consultancy firms we had identified. We extracted the year of establishment, 
location, mission statement, number of employees, services provided and partner or collaborator organizations 
from the English language version of the websites [38-43]. Due to the heterogeneity of information available on 
services and mission statements, information was coded inductively, and then at a later stage codes were merged 
and code families and networks were established, to best reflect the main themes emerging from the data. 
Finally, we investigated the quality of the HTA reports, understood as compliance with the submission 
requirements specified by the Ministry of Health (MoH) [44]. Specifically, we examined verification analyses 
(VAs), which are documents in which the AHTAPol appraises HTA reports [36]. We considered VAs issued in 
2012-2015 in which all four types of analyses included in this study (that is, clinical assessment, economic analysis, 
budget impact analysis, and rationalization analysis) were prepared by the same consultancy firm. We downloaded 
and analyzed the VAs in June 2018 and extracted data from sections in which the AHTAPol judged whether HTA 
reports had met the regulation on minimum requirements set out by the MoH [44]. For each company we calculated 
the percentage of HTA reports that met the MoH requirements among the total HTA reports. We also collected 
data from VAs on whether 1) at least one specific reason for not meeting the minimum requirements was provided 
by the AHTAPol; 2) the MoH requested the applicant to supplement the reimbursement application, including the 
HTA reports; 3) revised HTA reports were provided by the applicant; and 4) the revised HTA reports took into 
account the remarks for not meeting the minimum requirements.  
We analyzed all data descriptively in Excel. 
3. Results 
In total, we analyzed 336 manufacturer submissions, with 63, 80, 106 and 87 coming from 2012, 2013, 2014 and 
2015, respectively. We excluded 12 submissions as they were either not available online or were duplicated in the 
database. Duplication occurred when a manufacturer submitted exactly the same HTA report for different forms 
of administration of the same drug. We excluded six further applications because the analyses comprising the HTA 
reports were prepared jointly by more than one consultancy. Following on from this, 318 manufacturer submissions 
were analyzed (inclusion rate: 94.6%).  
3.1 Transparency: Identification of HTA consultancy firms 
The analyzed HTA reports contained 315 clinical assessments (CA), 314 economic analyses (EA), 313 budget 
impact analyses (BIA), and 242 rationalization analyses (RA). The company name was visible in 76%, 76%, 75% 
and 79% of the cases for CA, EA, BIA and RA, respectively. We were able to identify the HTA consultancy firms 
based on logos, document design or website links in additional 21%, 22%, 21% and 20% of the cases for CA, EA, 
BIA and RA, respectively. As a result, authors’ names were identified in 97%, 98%, 96% and 99% of the cases 
for CA, EA, BIA and RA, respectively. Transparency of the AHTAPol’s reporting in relation to consultancy firms 
increased steadily between 2012 and 2015, as the company name was visible in only around 40% of the cases in 
2012, and around 95% of the cases in 2015 (Table 2). There were 227 HTA reports where the same HTA 
consultancy firm was identified for all four types of analyses.  
3.2 Market structure: Calculation of market shares 
For those CA, EA and BIA analyses with identifiable authors, all analyses had been prepared by an HTA 
consultancy firm, while in case of RA there were 2 cases where we identified a drug manufacturer and no HTA 
consultancy firm.  
More than 90% of HTA report analyses were prepared by 6 HTA consultancy firms: HealthQuest, MAHTA, 
Instytut Arcana, HTA Consulting, Aestimo and Centrum HTA. (Table 3). During this period, HealthQuest had the 
largest market share with more than 25% for all four types of analyses. Two additional consultancy firms were 
identified, too, namely Pracownia HTA, NUEVO HTA. However, these companies prepared the analyses included 
in only 10 HTA reports over the four-year period. 
The market shares of the six major companies were relatively stable over the years. The largest changes were 
observed in 2014, when the market share of HealthQuest increased over 30% and the market share of Centrum 
HTA decreased below 5% (Appendix 2). While HealthQuest maintained its market leader position in each year, 
the company with the lowest market share varied. Nevertheless, each major HTA consultancy firm developed at 
least four HTA reports annually.   
3.3 Market size: Estimation of the HTA consultancy market 
Based on the Polish National Company Registry data, we estimated the average annual market size at 
approximately €5.5 million (details of the assumptions behind the analysis are included in Appendix 1/B). Based 
on the annual revenues and the annual number of HTA reports we considered that the average revenue per HTA 
report was €70 000. Since our market estimation reflects the number of HTA reports per year, the largest market 
size was observed in 2014 with more than €6.5 million, and the lowest was observed in 2012 with €4 million. In 
a scenario analysis assuming lower revenues per HTA report (€60 000), we estimated approximately €4.5 million 
average annual market size, with the highest in 2014 around €5 million and lowest in 2012 around €3.5 million. 
In a scenario analysis assuming higher revenues per HTA report (€85 000) we estimated approximately €6.5 
million average annual market size, with the highest in 2014 around €8 million and lowest in 2012 around €5 
million. 
3.4 Evolution and the key activities of HTA consultancy firms 
There were two waves of establishing HTA consultancy firms in Poland, with the first two companies established 
in 2002 (HTA Consulting and Instytut Arcana), while the remaining four major companies were established 
between 2008 and 2011. The two companies with minor market shares, Pracownia HTA and NUEVO HTA, were 
also established around the second wave, in 2010 and in 2012, respectively. There were two companies established 
in Warsaw (HealthQuest, MAHTA), which were also the market leaders during the study period. All remaining 
companies, including the two smaller ones, were based in Kraków. This also indicates that the market shares by 
the two largest cities were almost even (a little higher in Kraków). Numbers of employees were available only for 
four companies from their websites. The two oldest companies, HTA Consulting and Instytut Arcana had the 
largest number of employees with more than 50 and more than 40, respectively, according to their websites. HTA 
consultancy firms established in the second wave had lower number of employees with reportedly more than 20 
for MAHTA and 12 for Aestimo. We found no information on the number of employees in the remaining 
companies, including the market leader (HealthQuest).  
Companies’ mission statements were centered around supporting decision-making on medical technologies. Only 
one company (HealthQuest) did not state clearly in the mission statement that developing HTA reports was their 
core activity; instead, it implied as much by saying: “to support decision making in healthcare [based] on credible 
data and proper methods”. Evidence-based medicine is another key concept used by HTA consultancy firms, which 
appeared in the mission statement of several companies. Yet another key concept is credibility, since 4 out of the 
6 major companies mentioned it in their mission statement. Many mission statements emphasized the length of 
experience, especially in case of the more established consultancies, and the large number of HTA reports they 
had created.  
The service portfolio of HTA consultancy firms was very wide. The core service offered by all companies was 
preparing HTA reports including all types of analyses required by the MoH and the AHTAPol. Three or more 
companies provided the following additional specialized services: strategic consulting, preparing qualitative 
studies (surveys, interviews), qualitative database analysis, consulting on negotiation strategies with payer 
representatives, real world data analyses and training courses. One or two HTA consultancy firms provided the 
following services: participating in advisory boards, performing systematic literature reviews, conducting network 
meta-analyses, performing feasibility studies or rapid reviews and conducting epidemiological or 
pharmacovigilance studies.  
Two companies (Instytut Arcana, HTA Consulting) emphasized providing services outside Poland – in the Central 
and Eastern European region. Further, three companies mentioned partner organizations. Specifically, HTA 
Consulting established an alliance in collaboration with a Hungarian consultancy firm; Instytut Arcana was found 
to be part of a global organization in population health intelligence; and HealthQuest started a strategic cooperation 
with a company focusing on medical data management, statistics and programming. Collaborations with 
universities were not mentioned, although it was apparent that some companies key personnel had university 
affiliations as well (e.g. Warsaw School of Economics, Medical University of Warsaw and Jagiellonian University 
in Kraków). 
3.5 Quality of HTA reports evaluated by the AHTAPol 
According to the reviewed VAs issued by AHTAPol, out of the 227 HTA reports in which all four reviewed 
analyses were prepared by the same company, only 15 (6.6%) satisfied the minimum quality requirements set out 
by the MoH. According to the AHTAPol, 207 (91.2%) HTA reports did not meet the requirements, and the 
remaining five cases (2.2%) were unclear. The AHTAPol explained why the requirements were not met only in 
70 (33.8%) cases, did not provide any reasons in 136 cases (65.7%), and in one case a reason was redacted. Within 
reports that did not meet the requirements, the MoH requested the applicant to revise the HTA report in 162 
(78.3%) cases, and in the remaining 45 (21.7%) cases this was not clear from the VAs. Within the 207 reports that 
did not meet the requirements the applicant provided revised analyses in 157 (75.8%) cases. In 47 (22.7%) cases 
this was unclear, and in 3 (1.5%) cases revised analyses were not provided. Finally, we analyzed those sections of 
the VAs which reported whether the revised analyses took into account all AHTAPol’s remarks. From those 157 
revised analyses when the applicant provided revised analyses, 71 (45.2%) took into account the remarks, 62 
(39.5%) did not and in 24 (15.3%) cases it was not clear. 
There were small differences between the consultancy firms in the share of HTA reports not meeting the MoH 
requirements as reported by the VAs (Table 4). The highest percentage was observed for Centrum HTA (95%) 
and the lowest for HTA Consulting (88.9%) However, a relatively larger difference was observed in terms of the 
reasons for not meeting the requirements. In this regard, reports by MAHTA and Instytut Arcana received reasons 
by the AHTAPol for not meeting the minimum requirements in 39.5% and 39.3% of the cases, respectively. 
However, for instance reports by HTA Consulting received reasons for not meeting the requirements only in 21.9% 
of the cases. The percentage of HTA reports in which the MoH requested supplementing the reimbursement 
application ranged from 82.3% (HealthQuest) to 72.7% (Aestimo). The share of HTA reports for which revised 
analysis was submitted ranged from 79% (HealthQuest) to 68.2% (Aestimo). We observed a relatively large 
difference in the percentage of the reports in which the revised analyses took into account the AHTAPol’s 
recommendations for revising the analyses. Here, the rate of reports building on AHTAPol’s advice was the highest 
for Aestimo and HTA Consulting (60% and 56.5%, respectively); this rate was the lowest for MAHTA and 
Centrum HTA (33.3% and 30.8%, respectively).  
 
4. Discussion 
In this paper, we identified key players of the Polish HTA consultancy market for pharmaceuticals, described its 
size, structure and evolution, and analysed the AHTAPol’s comments on the quality of HTA reports prepared by 
HTA consultancy firms. Our research contributes to the literature on stakeholder involvement in HTA [45-47] by 
demonstrating that the scope of stakeholders in HTA to consider is broader and may include private-sector 
companies. Further, in contrast to studies focusing on later stages of the HTA process, especially the discussions 
held by appraisal committees, here we point to the less visible stage of technology assessment [28-30,36], which 
has so far largely escaped research attention. 
Researching HTA consultants reflects broader transparency challenges facing HTA systems. Unlike many public 
HTA bodies, expert consulting has no specific regulations pertaining to, for example, putting information on its 
activities in the public domain. The availability of information on consultants, then, largely depends on the 
openness of the public bodies with which they interact. In the field of HTA, any systematic examination of the 
market for HTA services requires, at the very least, publicly available HTA reports, which include the names of 
their authors. In this regard, countries like Poland, which adopted HTA later, can, perhaps surprisingly, could be 
more transparent than early adopters [36]. In this regard, consistent with recent research on the transparency of the 
AHTAPol’s work [30], we found that the transparency of information about the authors of HTA reports provided 
by the AHTAPol had improved steadily between 2012 and 2015. The evaluation of the quality of analyses 
developed by consultants requires even more detailed information about the outcomes of appraisal processes 
undertaken by HTA bodies. For instance, a recent study into HTA in Hungary was unable to use documentary 
analysis, unlike the present paper, because relevant data was not publicly available [6].   
We found that the HTA market for pharmaceuticals in Poland was dominated by six companies, with new market 
entrants unable to gain larger shares. This suggests that the dominant HTA consultancy firms have accumulated 
significant expertise and created strong working relationships with their clients. These findings are consistent with 
earlier research showing the sustained influence on the Polish HTA system of the first cohort of experts who 
received formal training in HTA [20,21]. A similar market structure including 3-4 major HTA consultancy firms 
was also found in Hungary, a country with a comparable HTA model and history [6]. Future empirical research 
could test whether this model holds in Western European countries. 
The size of the Polish HTA consultancy market for pharmaceuticals, estimated at €5-6 million annually, reflects 
Poland’s role as an important market in the region. Correspondingly, the market was almost two times larger than 
the same market in Hungary estimated at around €3-3.5 million annually using a similar method of calculation [6]. 
Notably, the size of Poland’s HTA market for pharmaceuticals considerably exceeds the AHTAPol’s annual 
budget of €2.5 million [48]. Similarly, with at the least 120 employees, HTA consultancy firms together dispose 
of significant manpower compared to the AHTAPol, which has 65 full-time equivalent employees [48]. The 
contrast between resources available to the public and commercial HTA sector is a function of the Single 
Technology Appraisal model of the HTA process, which confines the role of public HTA bodies to evaluating 
evidence submitted by manufacturers. In the Polish context, this model of HTA was introduced and solidified, via 
subsequent versions of AHTAPol’s HTA guidelines, largely based on contributions from experts from the major 
HTA consultancies [22-24]. In fact, the emergence of some of the first consultancies preceded the establishment 
of the AHTAPol as such, which can be interpreted as the public HTA body complementing the nascent HTA 
market, and not the other way round. This may be problematic, especially given the well-documented permeability 
of the commercial and the public HTA sectors, including high-level transfers from the AHTAPol to HTA 
consultancies, which potentially leads to conflicts of interest [19,20].  
Our results also suggest that HTA consultancy firms considerably expanded their services. They started their 
activities by preparing HTA reports for manufactures in the early 2000s [35], and although this remains their core 
activity, new types of services, such as strategic consulting, organizing training courses or preparing qualitative 
studies emerged throughout the years.  
Finally, our findings based on AHTAPol’s assessments of commercial HTA reports, called verification analyses, 
are perhaps the most puzzling. Here we established that the majority of HTA reports did not meet official MoH 
criteria, and only about half took into account the AHTAPol’s formal feedback in their resubmissions. Although, 
as noted below, our findings are themselves determined by the quality and consistency of reporting of relevant 
information by the AHTAPol, this finding raises concerns about a HTA process relying heavily on the quality of 
manufacturer submissions. Of course, the commercial evidence is scrutinized by AHTAPol’s staff developing 
verification analyses, and the number of shortcomings identified underscores the critical importance of the 
appraisal stage of the HTA process. However, the apparent scale of the problem is considerable, and is likely to 
translate into increased workload for the publicly funded HTA body, which, as mentioned above, is significantly 
under-resourced compared to the consultancy sector. 
The apparent low quality of HTA reports might have several reasons. One, it could suggest that the MoH minimum 
requirements are not fit for purpose and their guidance does not correspond to the practical possibilities of what 
data HTA consultancies, or perhaps their industry clients, can deliver. However, this interpretation does not sound 
plausible because there seem to have been no formal policy discussions on calls for the revision or refinement of 
the minimum requirements. Two, the AHTAPol might not use the requirements faithfully (e.g. by interpreting 
them overly strictly or expansively). To explore whether this is the case it would be important to check whether 
the scope of AHTAPol’s requests for revisions was consistent for all consultancies and pharmaceutical companies, 
to exclude possible preferential application of rules for some. Finally, some consultancies might have not 
understood the requirements and are unable, or unwilling, to learn from their past mistakes, as suggested by the 
variable and relatively low rates of companies taking the AHTAPol’s comments into account when submitting 
revised analyses. Given that the HTA consultancy market comprises just a handful of key players, this would be 
worrying and put a question mark over whether the HTA market operates in the public interest. 
Our study has several important limitations. First, our codebook for identifying the HTA consultancy firms was 
developed via an iterative process, possibly not identifying all authors. Second, the market size estimation is only 
a rough estimate, since data from the Polish National Company Registry was limited. Future research could 
possibly verify our indicative findings regarding the estimated market size via primary data collection from HTA 
consultancy firms. Third, the thematic analysis of the websites of the HTA consultancy firms relied on companies’ 
self-presentations. While this is useful to gain a sense of the companies’ public presence, it does not necessarily 
provide reliable information on the full spectrum of their business activities and priorities. Fourth, one specific 
part of the HTA reports, decision problem analysis, was not included in our study, given the lack of consistency 
in HTA reports. Finally, our analysis of the quality of HTA reports was limited to the understanding of “quality” 
as per the minimum quality requirements by the Ministry of Health, which could be better framed as formal 
completeness or comprehensiveness of HTA reports, rather than an assessment of more substantive quality issues 
such as the choice of comparators or validity of economic models. Furthermore, the information included in 
verification analyses was often unclear, which is why we were unable, at times, to collect the explicit reasons of 
why HTA reports did not meet the official requirements.  
5. Policy recommendations 
Based on our Polish case study, we can extrapolate several takeaways regarding HTA consultancy markets for 
other countries, particularly those that rely on the STA model. First, there is a clear need for detailed reflection on 
conflicts of interest that may emerge at the intersection of public HTA bodies and HTA consultancies. The 
permeability of the two sectors is likely not a Polish exception and appropriate, context-specific regulation of the 
“revolving door” in HTA should be considered. Second, when HTA reports are not meeting the official 
requirements, further investigations are required to explore the underlying reasons. Third, HTA bodies should 
periodically subject their relationships with individual HTA consultancies to conduct critical analysis to eliminate 
potential bias. Fundamentally, to allow for external analysis, public availability of documentation of HTA 
submissions, including information on authors of HTA reports, is paramount to ensure the transparency of the 
HTA process. Reasons for confidentiality of this information should be re-interrogated in countries that practice 
extensive redactions or do not make HTA documentation public.  
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Appendix 
Appendix I: Detailed methodology of applied methods 
I/A: Identification of HTA consultancy firms 
Since the documents of HTA reports were frequently redacted we scanned them carefully to identify any feature 
of HTA consultancy firms that could be helpful (i.e. company logos, document design and style or website links 
within the text). From these features a code book was developed. This was an iterative process, therefore our 
codebook was evolving during the data extraction. When our codebook was considered to be complete after 
reviewing the documents of the first two years (2012, 2013), we re-evaluated those, where the HTA consultancy 
firm was not identified and double checked those that were already identified. We had separate coding for those 
documents where the company name was not blacked out, and for those when the name was blacked out and our 
codebook was used to identify the company. 
I/B: Estimation of the market size 
Annual net revenues from sales provided by the Polish National Company Registry was used in order to estimate 
market size. Since the received net revenue data was available only for two of the major HTA consultancy firms, 
these were used as bases for estimating the total market with the following calculations. First the annual net 
revenues were divided by the annual number of submitted HTA reports in case of the two companies for each 
years. Then the mean of these ratios was multiplied with the annual number of submissions for those companies 
where data was missing on the net revenue. The sum of these multiplications were used for estimating the total 
market size. In scenario analyses the lowest and the highest ratios of the annual net revenue / annual number of 
submitted HTA reports were used. These calculations assume that the major HTA consultancy firms in Poland 
generate similar revenue at company level by preparing an HTA report. Although this assumption cannot be 
validated, this method seemed to be the only reasonable option for the market size estimation within the scope of 
this study. Since we aimed to calculate a rough estimate, data was not corrected for inflation and current exchange 
rate from 2018 July was used to express values in EUR. Further data from the Registry’s website was scrapped to 
complement information collected from the companies’ websites on year of establishment and location. 
Appendix 2: Market share of consultancy firms according to the four types of analyses in the HTA reports reported for each years of the study interval 
Clinical 
assessment 
No. analyses Health Quest Mahta 
Instytut 
Arcana 
HTA 
consulting 
Aestimo 
Centrum 
HTA 
Other firms Not identified 
2012 57 22.8% 10.5% 14.0% 21.1% 8.8% 10.5% 3.5% 8.8% 
2013 75 30.7% 21.3% 14.7% 12.0% 9.3% 10.7% 1.3% 0.0% 
2014 98 33.7% 13.3% 14.3% 13.3% 14.3% 4.1% 5.1% 2.0% 
2015 85 22.4% 18.8% 16.5% 14.1% 8.2% 14.1% 4.7% 1.2% 
Economic 
analysis 
No. analyses Health Quest Mahta 
Instytut 
Arcana 
HTA 
consulting 
Aestimo 
Centrum 
HTA 
Other firms Not identified 
2012 57 24.6% 10.5% 12.3% 21.1% 10.5% 10.5% 3.5% 7.0% 
2013 75 30.7% 21.3% 14.7% 12.0% 9.3% 10.7% 1.3% 0.0% 
2014 97 34.0% 13.4% 14.4% 12.4% 14.4% 4.1% 5.2% 2.1% 
2015 85 22.4% 18.8% 16.5% 14.1% 8.2% 14.1% 4.7% 1.2% 
Budget impact 
analysis 
No. analyses Health Quest Mahta 
Instytut 
Arcana 
HTA 
consulting 
Aestimo 
Centrum 
HTA 
Other firms Not identified 
2012 56 23.2% 10.7% 10.7% 21.4% 8.9% 10.7% 3.6% 10.7% 
2013 74 28.4% 21.6% 14.9% 12.2% 9.5% 10.8% 1.4% 1.4% 
2014 98 33.7% 13.3% 14.3% 12.2% 14.3% 4.1% 5.1% 3.1% 
2015 85 22.4% 18.8% 16.5% 14.1% 8.2% 14.1% 4.7% 1.2% 
Rationalization 
analysis 
No. analyses Health Quest Mahta 
Instytut 
Arcana 
HTA 
consulting 
Aestimo 
Centrum 
HTA 
Other firms Not identified 
2012 40 27.5% 12.5% 5.0% 20.0% 7.5% 7.5% 7.5% 12.5% 
2013 58 29.3% 25.9% 8.6% 13.8% 6.9% 10.3% 1.7% 3.4% 
2014 74 35.1% 13.5% 17.6% 13.5% 13.5% 4.1% 2.7% 0.0% 
2015 70 22.9% 20.0% 14.3% 15.7% 10.0% 11.4% 4.3% 1.4% 
 
 
